Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...
Irish Independent on MSN2d
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback